



Published in final edited form as:

Int J Drug Policy. 2025 May ; 139: 104789. doi:10.1016/j.drugpo.2025.104789.

The Police Opioid Seizure Temporal Risk (POSTeR) Model of increased exposure to fatal overdose

Brandon del Pozo, PhD, MPA, MA,

The Warren Alpert Medical School of Brown University Rhode Island Hospital

Traci C. Green, PhD, MSc,

Opioid Policy Research Collaboratory, Brandies University COBRE on Opioids and Overdose, Rhode Island Hospital Departments of Emergency Medicine and Epidemiology, Brown Schools of Medicine and Public Health

Morgan Godvin, BA,

San Diego State University

Bradley Ray, PhD

RTI International

Abstract

Context: Police seizures of illicit opioids remain a dominant strategy for addressing problematic substance use and overdose in the United States and throughout the world, yet qualitative accounts and quantitative analyses exhibit positive associations between police opioid seizures and ensuing risk of fatal overdose at the local level of individual incidents. Since these associations run counter to the commonly held belief that removing potent illicit substances from the community is protective of overdose, a causal model is needed to demonstrate this association and convey the overdose risks that follow from police opioid seizures.

Methods: Leveraging well-established biological and psychological outcomes of opioid use disorder and opioid supply interruption, our analysis presents the Police Opioid Seizure Temporal Risk (POSTeR) Model, an individual-level casual model that begins at the point of opioid dependence, introduces an interruption to an individual's supply of opioids as the result of a police drug seizure, and presents the physical and behavioral outcomes that increase the ensuing temporal risk of fatal overdose.

Corresponding Author: Dr. Brandon del Pozo, DGIM Research, Rhode Island Hospital, 111 Plain Street, Providence, RI 02903, bdelpozo@brownhealth.org.

Conflicts:

The authors have no conflicts of interest to declare.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Results: The aftermath of a police opioid seizure can increase a person's risk of fatal overdose. The urgent need to prevent or reduce acute opioid withdrawal symptoms leads people to seek a replacement supply, while reduced opioid tolerance resulting from post-seizure involuntary abstinence combines with the uncertain potency of a replacement supply of illicit opioids to significantly increase the difficulty of administering a safe but effective dose. In the face of these hazards, people in withdrawal often have a reduced aversion to risk, prompting them to consume this uncertain dose in a manner that increases their exposure to overdose.

Conclusions: Strategies that emphasize police opioid seizures as an acceptable way to reduce the prevalence of illicit drugs in a community without accounting for the elevated risk of fatal overdose that results can worsen one of the most significant problems they are meant to address.

Keywords

substance use; opioids; overdose; policing; drug enforcement

Introduction

A growing body of evidence shows that when a person is dependent on opioids, temporarily interrupting their supply of the drug exposes them to an increased risk of overdose (Hochstatter et al., 2023; Mark & Parish, 2019; Williams et al., 2020). The first studies about interruptions originating from police drug seizures explored this assertion qualitatively, finding that people problematically dependent on opioids reported this increased risk when asked about their personal experiences (Carroll et al., 2020; Rhodes et al., 2019; Victor et al., 2020). Conversely, these and other studies found people who use drugs (PWUD) with steady access to a supplier they could trust, who provided a basically consistent supply, could warn of inconsistencies, and who might supply naloxone, was protective of overdose (Carroll et al., 2020; Hedden-Clayton et al., 2024). More recently, a quantitative analysis found a statistically significant spatiotemporal association between police opioid seizures and overdose during a two-year period in Indianapolis, Indiana (Ray et al., 2023). In accordance with studies that show ecological associations at the state and county levels (Cano et al., 2024), the analysis found that fatal overdoses doubled within three weeks of the police seizure, in a radius of up to 500 meters from the seizure's site, and this association held when considering all quantities of opioids seized, regardless of whether they were taken from a dealer or an individual who uses drugs (Ray et al., 2023).

Many people find the conclusion that police drug seizures increase overdose risk strongly counterintuitive, considering that governments act to interrupt the supply of illicit drugs to ostensibly reduce risk and save lives. To that end, the presumption is that reducing the quantity of illicit drugs in circulation and interrupting their consumption by people dependent on opioids is believed to reduce risk. But at least in the proximate sense, the evidence does not bear this presumption out. To address this gap between emerging research findings and many people's intuitions, and to promote the rigorous interrogation of this proposition, this paper presents the discrete causal model by which increased exposure to overdose arises from the aftermath of a police drug seizure, a phenomenon that has critical implications for our present public health and drug enforcement policies. In doing so, it intends to bolster our understanding of the health outcomes of police drug enforcement

and suggest ways to interrupt the causal chain to reduce overdose mortality. Barring such a model, the evidence we produce to explore this relationship will continue to face its inherent limitations. Qualitative research conveys the lived experience of increased exposure to overdose in the aftermath of police drug seizures with nuance, but the method inherently precludes broad generalizability. In contrast, quantitative analyses of administrative data can demonstrate statistically significant associations, but do not readily illuminate the causal pathways that suggest where to effectively intervene. Both veins of research would benefit from the development of a model that conveys how personal experience and quantitative correlation can be understood as causation. By presenting such a model here, this paper provides guidance about where future research on this topic should go, and what intervention designs might look like.

The model we present takes policing as its primary focus. It concerns the events that we commonly understand to be police drug seizures: the arrest of people for drug possession, the seizure of contraband drugs that people preemptively discard to avoid arrest by police, and the arrest of distributors and suppliers accompanied by the seizure of their drugs as evidence. It does not distinguish between the volume or target of the seizure; it could consist of the arrest of an individual person and the seizure of their own supply, or the seizure of a dealer one or more steps up the supply chain. The inclusion criteria for the model are only that opioids are seized by police, and in a manner that ultimately interrupts supply at an individual level. The model therefore operates at these lower geographic resolutions, during the relatively short time frames considered in Ray et al. (2023), and does not intend to offer explanatory power across larger ecologies such as cities, counties, or states, or over longer periods of time.

The model here takes up overdose as the exclusive outcome of interest, although there is evidence that police drug seizures can increase the risk of other harms as well. In the aftermath of police contact, people may change the way they consume drugs, for example, speeding the act of injection or sharing syringes (Cooper et al., 2005; Werb et al., 2008), thereby increasing the risk of abscess and infectious disease (Baker et al., 2020). To keep our causal model as direct and compelling as possible, these other outcomes will not be its focus. In the same vein, while the model here pertains to policing, and is not intended for general application across the criminal justice system. Release from a period of incarceration is a prime example of another event that substantially increases risk of overdose (Binswanger et al., 2011; Binswanger et al., 2007), and researchers have presented the corresponding conceptual framework (Joudrey et al., 2019), while emphasizing the particular role of fentanyl in generating these overdoses (Brinkley-Rubinstein et al., 2018). We intend to complement this research with a pragmatic realist account (Cherryholmes, 1992) of overdose risks that occur upstream, at the point of police encounters, prior to a period of imprisonment. In its realist approach, our account asserts that prevalent scientific and behavioral theories accurately describe the aspects of the world they were created to explain (Leplin, 1984; Psillos, 2005). We further assert that their individual explanatory mechanisms can combine to produce an accurate, predictive understanding of an overall phenomenon (Leplin, 1984), in this case, increased overdose risk after a police drug seizure. In this way, our approach is in the tradition of scientific realist evaluation (Pawson & Tilley, 1997), where outcomes arise from interactions between mechanisms and their social

contexts, and causal mechanisms can be reliably identified through reductionist theorizing (Jagosh, 2020). The model's pragmatism lies in providing insights and recommendations that acknowledge the current political and social contexts of substance use and policing.

The paper will proceed as follows: it will present widely accepted principles of pharmacology, accounts of how opioid dependency biologically influences the behavior of PWUD, and research about how both the mechanics and social dynamics of policing and substance use further affect these behaviors. Taken in sum, we will argue they combine to elevate overdose risk, and we will present these relationships in a graphical model, i.e., a causal diagram (Greenland & Brumback, 2002) entitled the Police Opioid Seizure Temporal Risk (POSTeR) Model. We close by discussing several policy responses to the risks the model presents, stressing that there are potential ways to mitigate overdose risks that result from seizures, although they vary in feasibility and acceptability given individual contexts and political climates. We then discuss POSTeR Model's limitations and suggest avenues for further research.

Principles underlying overdose as a result of drug seizures

There are five factors that drive our model, each one an evidence-based premise that combines to increase fatal overdose risk when a personal drug supply is interrupted by a police drug seizure. They may present as contributory causes that are insufficient to decisively increase fatal overdose on their own, but that synthesize to do so. In that sense, they build on each other to produce increased risk. The principles are as follows:

1) Supply interruption sends people who are physically dependent on opioids into withdrawal, and the most common outcome is that they will avoid or reduce the condition with a replacement supply of opioids (Frank et al., 2023; Hall et al., 2024).

Opioid dependence is defined by the physical experience of opioid withdrawal, its psychological toll, and the ways in which they guide and modify behavior (Pergolizzi Jr et al., 2020). The most common responses to the onset of opioid withdrawal are to avoid it, reduce it, or reverse it (Bardwell et al., 2021; Frank et al., 2023; Mateu-Gelabert et al., 2010), which sets the stage for the challenges presented by the other principles below. For many people, relief requires gaining access to a replacement supply of opioids (which could include treatment medications) or being forced to endure a period of detoxification that is, by all accounts, extremely painful and difficult to bear (Dunn et al., 2023; Shah & Huecker, 2018). Its symptoms can last weeks (Ware & Dunn, 2023), and are potentially life-threatening (El-Sabawi, 2024), and therefore motivate strong survival behaviors. The idea that a person with problematic opioid dependence can detoxify by enduring a few days of discomfort reflects a deep misunderstanding of the physiological processes and changes to the body and brain that have occurred when a person is heavily dependent on opioids (Monroe & Radke, 2023). In response, some may attempt to manage the symptomatic presentations of their withdrawal by means such as benzodiazepines, sedatives, cannabis, or other substances, which may provide some relief to individual symptoms without alleviating withdrawal themselves, and which may present the additional risks discussed in Principle 5 below.

2) Supply interruption reduces a person's tolerance of opioids to a degree they cannot measure with precision, making dosing more hazardous.

Withdrawal, in and of itself, is insufficient to elevate a person's overdose risk. If a person were to know the dose necessary to alleviate it, and had reliable access to that dose, the resulting risk would be reduced. An initial challenge, therefore, is establishing a safe dose, since even short interruptions in the supply of opioids affect a person's tolerance of the substance. As prolonged use generally increases tolerance, such that greater quantities are necessary to avoid withdrawal, produce a euphoric effect, or simply maintain bodily homeostasis (Dumas & Pollack, 2008; Freye & Latasch, 2003), interruptions have the opposite effect (Kesten et al., 2022), which is why physicians may alter the dose of patients who use prescribed opioids if there is cause to believe they have diminished tolerance (Gökçınar et al., 2022; Jeffery et al., 2020).

It is critical to note, however, that several factors affect the actual loss of tolerance, from genetic predispositions to body composition (Byanyima et al., 2023; Lötsch et al., 2004; Na et al., 2024; Wilder-Smith, 2005), preventing the precise measurement of this reduction. While these variables and a lack of research prevent accurate predictions about the tolerance lost by a particular person after a given period of time, the warnings provided to patients about resuming opioid use after discharge from inpatient detoxification advise that a potentially fatal loss of tolerance can occur within a few days (META PHI, 2024). In sum, when a person resumes consumption, it will be with a tolerance for opioids that is reduced by an uncertain amount, making dosing much more a matter of estimation than it would otherwise be.

3) The replacement supply of illicitly produced opioids sought in the aftermath of a seizure event is likely to be of a different, uncertain potency than the interrupted one, further compounding the hazards of dosing.

While an indeterminate reduction in tolerance prevents a person from gauging the dose necessary to safely and effectively address withdrawal symptoms, the replacement opioids procured in an illicit market compound this risk by being of an unknown potency regardless (Rosenblum et al., 2020). In saying this, it is critical to note that we do not mean the new supply is likely to be more potent. In presenting our model to nonspecialist audiences at practitioner-oriented conferences as an accompaniment to quantitative findings about the relationship between police opioid seizures and overdose, one misconception that frequently arose was that initial heroin supplies were replaced with a resupply of fentanyl. Our model does not depend on pharmaceutically produced opioids or heroin being replaced by fentanyl. Instead, it presumes that fentanyl has saturated the nation's illicit opioid markets (Zoorob, 2019; Zoorob et al., 2024), is what people who use illicit opioids are likely to consume, and what replacement supplies most likely consist of. The variability in potency that powers the model here arises from the heterogeneity in which illicit opioids are cut for distribution to the end user (Ivsins et al., 2020; Larnder et al., 2022; Tobias et al., 2021), and the unsuspected presence of fentanyl in counterfeit analgesic pills (Friedman & Ciccarone, 2025; O'Donnell et al., 2023). Since illicit manufacturing and packaging processes are not carried out to any standard, or with reliable precision, barring the illicit consumption of

pharmaceutically produced opioid analgesics, there will most likely be variance between the potency of an initial supply of illicit opioids and its replacement.

4) People experiencing opioid withdrawal have a reduced aversion to risk, causing them to discount these hazards.

Finally, while PWUD who use drugs often understand the preceding problems, the risks they pose are often insufficient to deter them from consuming replacement opioids, or doing so in a safer, more cautious manner (Hall et al., 2024). It is well-documented that the symptoms of opioid withdrawal range from extreme discomfort to acute pain and trauma (Bluthenthal et al., 2020). The motivation to reduce these symptoms is compelling, and can lead people to take risks solely for the need to escape the sensation of withdrawal (Frank et al., 2023). Such risks are wide-ranging, and while many do not apply to this model, they illustrate the powerful forces at work. For example, people may engage in criminal activity to obtain funds for drugs, patronize unfamiliar drug dealers with uncertain reputations, use replacement substances of unknown quality (perhaps using them by a new and unfamiliar route of administration), and engage in unprotected, risky sex work. In our model, however, we posit that one of the risks a person will be significantly less averse to is consuming a replacement opioid supply of an uncertain potency, and doing so in a more risky manner than if they were not experiencing withdrawal (Mateu-Gelabert et al., 2010), such as by rushing consumption, neglecting to test the dose for potency, or to ensure other people are present in the event of an emergency, preferably with naloxone on hand. In other words, not only is a person in these circumstances likely to encounter an uncertain replacement supply that will have an unknown interaction with their newly-reduced tolerance, but they will be less averse to consuming it regardless, and to doing so with few or reduced protective measures, even if they are aware of the attendant risks.

5) Efforts at self-medication after a police opioid seizure can also increase risk of overdose.

If a person loses their supply of opioids and begins to experience withdrawal, other factors may contribute to their overall overdose risk in addition to ones directly tied to a sequence of withdrawal, loss of tolerance, replacement supplies of uncertain potency, and reduced aversion to risk. For example, people may seek sedatives or other substances to alleviate symptoms until they can resume opioid use or fully detoxify, such as by taking prescribed or illicit benzodiazepines or kratom (Boyer et al., 2008; Preiss et al., 2022). This alternative poses its own set of risks. Benzodiazepines compound the respiratory depression of opioids, and can cause overdose if they are consumed together or in close succession (Sun et al., 2017). Moreover, the illicit market for sedatives has been heavily compromised by counterfeit pills (Friedman & Ciccarone, 2025), introducing the dangers of uncertain dosing discussed above (O'Donnell et al., 2023).

There is also an ancillary factor that plays a role in the model: **the margin of error for correctly dosing fentanyl and other powerful synthetic opioids is very small.** The challenge of safely dosing illicitly-supplied fentanyl is driving the present wave of the nation's overdose epidemic (Zoorob, 2019; Zoorob et al., 2024), since a comparatively small difference in the volume of this powerful synthetic in a given dose, or its presence in other

substances, can spell the difference between safe use and overdose for many consumers. Not only does dosing vary by supply source, merchant, and batch (given the *ad-hoc* means of preparing and packaging drugs for smuggling and consumption), but for any unit of difference in the amount of opioid in a supply, the dose is going to be much more potent if it is a unit of fentanyl than some type of less potent alternative. We consider this an ancillary factor because the model suggests people whose supply of illicit opioids are interrupted by a police seizure will suffer an increased risk of fatal overdose regardless of the type of opioid involved. Rather, highly potent synthetic opioids such as fentanyl greatly increase the magnitude of this risk because any given unit of inconsistency represents a much greater variance in potency than the variance per unit found in heroin or pharmaceutically produced analgesic pills.

The causal model

The POSTeR Model proceeds through the eleven parts presented in Figure 1 as follows. The figure's solid arrows represent causal relationships with no alternatives in the model, and the dotted arrows represent possible branches. Green arrows signal ways to lower risk, and red signals a pathway to elevated risk. The underlying principles presented above appear in the figure both when they first manifest, and then when they combine to ultimately produce elevated overdose risk.

Parts 1 through 4 present the basic stasis of consistent supply for people who have transitioned from opioid use to a state of dependence. A person with opioid dependence **(1)** exhibits increasing physical and psychological dependence on opioids **(2)**, as well as an increasing pharmacological tolerance for the effects of the drug **(2)**. As their tolerance increases, the general consistency of their supply **(3)** allows them to adjust their dose accordingly. There is still risk to this behavior, including instances of polydrug use that can introduce unpredictable variables (Peppin et al., 2020) and the inherent instability of an illicit drug supply (Holland et al., 2024), but this general consistency in comparison to a seizure event means that the person's opioid supply is not exceedingly difficult to dose as needed, thereby reducing overdose risk (Carroll et al., 2020). Overdose may still occur, but these protective factors make it less likely to be fatal **(4)**, or imprecise dosing may not be sufficient to alleviate withdrawal and lead to the risks that arise from repeat dosing **(4)**. The result is the continued cycle of opioid dependence as described above, which can last for years or decades. People may exit this cycle over time, in which case they would leave the model by completing the withdrawal period and not re-initiating use, or by entering treatment **(5)**. It is worth noting most people who are dependent on opioids do not fatally overdose (Degenhardt et al., 2011), can age out of problematic use (Jones et al., 2020; Kelly et al., 2017), may contend with intermittent cycles of substance use and recovery over the course of years or decades (Hser et al., 2001; Hser et al., 2015), and may enter remission of their own accord (Mocenni et al., 2019).

For the person actively dependent on opioids, the path toward an elevated exposure to fatal overdose begins with the type of supply interruption that results from a police opioid seizure **(6)**. The interruption could be the result of an arrest of the person, or their supplier; either event deprives the person of the opioids necessary to maintain their cycle of use

and suffices to bring about the physical effects of involuntary abstinence: withdrawal and decreased tolerance (7). These effects produce efforts to avoid withdrawal with a new opioid supply or self-manage it using sedatives or cannabis combined with reduced aversion to the risks associated with consuming these substances (8). The result is seeking a replacement substance of uncertain potency, especially if it is from a new dealer, although this variance is ultimately dependent on the structure and sources of the community's drug supply network (9). Consuming the replacement supply constitutes an elevated hazard because it occurs at the nexus of two risk factors and a catalyst: a reduced but indeterminate tolerance to opioids, an uncertain potency that precludes accurate dosing (compounded by not knowing what that dose should be in light of lowered tolerance), and the reduced aversion to risk that comes with avoiding or escaping opioid withdrawal (10). This reduced aversion means that even if a person apprehends the pending hazards, they will disregard them, and/or engage in the additional risk behaviors described in the next section. This results in a significantly increased exposure to the risk of fatal overdose (11).

At any point in the model, a person can attempt to enter treatment, and if it was effective, they would leave this causal pathway. A return to use, however, will place them back in the pathway at (9), facing overdose risk. While many factors motivate a person's return to use, from social pressures to trauma, pain, stress, and deeply-ingrained triggers (Childress et al., 1988; Dennis, 2016; Massaly et al., 2016), the decision necessarily indicates they have become less averse to the risks of opioid misuse. Since their new drug supply will be of an unknown potency, and their tolerance will be significantly reduced by some indeterminate amount, it may affect them in unknown ways. This accords with research that a return to use after a period of abstinence poses an elevated risk of overdose compared to the risks a person faced if they were consistently supplied when they were dependent on opioids (Hser et al., 2015; Kumar, 2016). The model as related here is therefore neither directed, nor acyclic. People can remain in a basic stasis given a consistent supply of opioids, although escalating frequency and volume of use as dependence and tolerance increase, and treatment can either remove them from the cycle entirely, or, with a nonfatal relapse, can return them to the provisional stasis expressed by steps (1) through (4) of the model.

Other behavioral responses to police drug seizures

Our model is principally driven by physiological factors. For example, reduced aversion to risk arises from the need to limit acute physical withdrawal symptoms. There are other behavioral factors, however, that emerge from a risk calculus that is not driven by biological and pharmacological concerns but instead result from decisions meant to reduce the probability of additional supply interruptions by police, or tactics to quickly reduce or reverse withdrawal that constitute riskier behaviors. We describe five of them here and note in step (10) that they fit our model as additional causes of risk at the point of consumption that compound those arising from the causal process described above.

- **Use in private places.** In order to avoid the attention of police, especially when a prior seizure was the result consuming drugs in public, people who use drugs may shift to doing in more secluded or private places, such as indoors, in tents, or in vehicles. Using in private spaces decreases the likelihood that someone who

is overdosing will be discovered and revived in time to avert death or irreversible injury.

- **Using alone.** Regardless of whether the person is using in public or not, solitary use increases the risk of fatal overdose. Many people consume drugs alone to protect themselves from exposure to police or to limit their visibility to other people, who may call police or otherwise express the stigma associated with drug use (Hanoa et al., 2024). When someone is in withdrawal, using alone rather than seeking out trusted people who can observe the results may be a response to the need for rapid abatement of physical symptoms, which can increase such risk-taking behavior (Rosen et al., 2023).
- **Electing not to keep naloxone on hand.** PWUD and their associates may believe carrying naloxone elevates the suspicion of police and may increase the risk of a seizure (Bennett et al., 2020; Smyth, 2017). If that is the case, PWUD may elect not to have it on hand in the hopes of averting seizures, creating the risk that it will not be available to avert a fatal overdose.
- **Rushed consumption.** If a person believes they have no option but to consume drugs in public, but a prior seizure leads them to fear police intervention, they may rush the process of consumption (Suen et al., 2022; Ti et al., 2015), which runs counter to the harm reduction adage of “start low, go slow” (Aleixo et al., 2024; Collins et al., 2024). When consuming a new supply of drugs, a user can test a small quantity of the substance and then adjust the dose as its potency becomes clear, but rushed consumption increases risk as people use a larger amount sooner, either to avoid arrest or to abate withdrawal.
- **Hesitance to seek help for an overdose.** People present at the scene of an overdose may be hesitant to seek help if it ultimately means calling 9–1–1, for fear that police will respond and make arrests (Weisenthal et al., 2022). People in recent contact with police that resulted in a drug seizure may likewise hesitate to seek help when they witness an overdose or call 9–1–1 if they witness one, out of the fear of arrest and another drug seizure (Byles et al., 2024; van der Meulen et al., 2021). This may lead them to hope the overdose passes without turning fatal rather than try to reverse it. When they do call, people may downplay or obscure the fact that an overdose emergency is occurring (Atkins et al., 2024). Although this may result in medical personnel being dispatched without police, it may also delay the administration of naloxone of police officers who were poised to arrive first (Pourtaher et al., 2022; White et al., 2022), elevating the risk of death or serious morbidities.

Implications for policy and practice

The POSTeR Model allows us to examine the points at which overdose risk can be averted or reduced. We present them along a general arc from the interventions that are likely to be the most feasible and acceptable given the present policy environment to the ones that would require more significant shifts in norms, laws, and culture, with the interventions requiring the most significant shifts likely to be the ones that offer the greatest potential

to reduce the overdose risks described by this model. In sum, these interventions work by either preventing the move from risky use **(10)** to fatal overdose **(11)** by shunting people back toward a comparatively safer stasis or better equipping them with safer supplies **(1–4)** by referring them to medications to treat opioid dependence **(5)**, or moving further upstream and preventing disruptive supply interruptions **(6)** in the first place, promoting the ability of people with opioid dependence to consume drugs with a greater level of consistency prior to entering treatment **(5)**, which is in and of itself a possible intervention. Another possibility, as discussed above, is that a person may eventually desist from substance use over time (Jones et al., 2020; Kelly et al., 2017), an outcome common to many problematic social behaviors (Sampson & Laub, 1993), since most people with opioid dependence do not fatally overdose (Degenhardt et al., 2019). Given this approach, the following are possible changes to policy and practice that would prevent, interrupt, or reduce overdose risk related to opioid seizures.

Cautionary publicity about police drug seizures, especially notable incidents

Official acknowledgement that police drug seizures can increase risk of overdose would alert people dependent on opioids to the impending hazards and empower them to better manage the risks. Such an acknowledgment could also pave the way for warnings about particularly notable seizure incidents. For example, public officials in Manchester, New Hampshire issued a warning to the community that police had made a significant high-level drug seizure, and deployed overdose response teams to the area concerned as a protective measure, emphasizing both harm reduction measures and linkages to MOUD (Barndollar, 2023; McFadden, 2023). In doing so, they explicitly cited the Ray et al. (2023) study that associated police drug enforcement with increased overdose. Such public measures remain rare, however, since they hinge on the still counterintuitive recognition that police drug seizures, despite the goal of reducing harm, can have the proximate effect of increasing them.

Linkage to MOUD

Linking people with opioid dependence to the medications that can effectively treat it interrupts the pathway to overdose by removing the risks associated with consuming illicit opioids of any potency (National Academies of Sciences Engineering & Medicine, 2019). In our model, it forecloses overdose risk by statically positioning the person at step **(5)**. It does not, however, address the risks faced by people who are pre-contemplative about treatment and seek a replacement supply as withdrawal sets in, which will be most of the population of concern at any given time. Moreover, as our model reflects, relapse from treatment back to substance use places a person at elevated risk by moving them through the model to **(10)**, as a person will resume substance use with a supply of unknown potency and a diminished but unknown tolerance as discussed above. Linkage to MOUD also requires that there be sufficient and immediate access to medications in the aftermath of a seizure.

Despite these limitations, linkage to MOUD in the aftermath of a police drug seizure will remain an appealing policy option because it is the least contested and controversial response: it signals a person's efforts to make a decisive change in their own exposure to overdose risk that is less susceptible to the stigma and biases that typically accompany harm

reduction efforts and legal reforms. Despite this appeal, as a response that intends to prevent overdose and save lives, linkage to MOUD will not offer protection to most people whose drug supply is interrupted by a police opioid seizure. Even the most robust, low-barrier linkages to MOUD will only impact people who actively seek out the medication or choose to engage with the treatment that is offered to them. This is a small minority of the at-risk population of PWUD at any time, most of whom are not contemplating treatment and would not accept MOUD if it were offered to them.

Because successful engagement with MOUD requires a change in behaviors entrenched by habits and biological dependence, assessing where an intervention offers its protections among the Stages of Change (Norcross et al., 2011; Prochaska & Norcross, 2001) can clarify the subpopulation of PWUD it is most likely to reach, and help assess the collective reach of an array of measures. By such an analysis, MOUD does not reach people in a state of precontemplation, i.e., the majority of PWUD at a given time (Mann, 2023; Patton & Best, 2024). As illustrated in Figure 2, the interventions below are more likely to fill the resulting gap by offering protection from overdose prior to a decision to change drug consumption habits or enter recovery. It suggests the most effective lifesaving response is a comprehensive one.

Community naloxone distribution

While the distribution of naloxone to lay persons in the community for the purposes of overdose reversal has gained increasing political and cultural acceptance, its success depends on saturating at risk communities with a quantity of naloxone substantial enough to be used in a meaningful number of overdose events. Success in this regard would require a large, sustained investment in naloxone programs targeted to PWUD and the people who are present with them when they consume drugs (Doe-Simkins & Wheeler, 2025). At the individual level, community naloxone distribution would interrupt the model when two conditions are satisfied: a person uses drugs in the presence of someone who abstains from risky drug use or coordinates their own use to prevent simultaneous overdose, and that person has access to, or can feasibly summon a bystander with naloxone. Meeting these two conditions, moves people from instances of dangerous use (10) back toward stasis (1–4). Given Ray et al. (2023)'s findings that overdoses increase within 500 meters of a seizure event over the following weeks, the targeted distribution of community naloxone in the aftermath of a seizure could be particularly effective.

Access to harm reduction services and education

Harm reduction interventions would directly supply people dependent on opioids with naloxone and the knowledge necessary for its effective administration, in doing so reducing risk among people well prior to the point of substantial change in their drug use behavior (see Figure 2). As people in drug-using communities facing greatly elevated overdose risks, this manner of naloxone distribution has the potential to be more effective than widespread distribution or distribution to first responders (Townsend et al., 2020) by making the medication more likely to be present at the times and places where overdose occur, especially if PWUD are more likely to consume drugs together, rather than in the presence of non-using community members. Harm reduction services can also offer education and

training about the importance of “going slow” (i.e., not rushing consumption), and not consuming drugs alone, while innovative measures include prescribing medications such as single-dose buprenorphine (Ahmadi et al., 2018; Ahmadi et al., 2020) or using cannabis or sedatives as a temporary form of withdrawal support (Meacham et al., 2022; Wiese & Wilson-Poe, 2018), thereby reducing the risks that come with withdrawal-motivated behaviors. Together, these interventions can reduce the probability that a person proceeds from step (10) of the model to fatal overdose (11) by shunting them back toward comparative stasis (1–4), and decreasing the incidence of other risky behaviors that can occur after a seizure discussed above. Harm reduction services can also provide people dependent on opioids with linkage to treatment (5).

Drug checking services

Analyses of the composition of drugs performed by community drug checking programs can likewise reduce overdose risk by providing reliable information about what a replacement substance may contain (Green et al., 2022). They may be especially useful if a person resorts to a replacement substance such as opioid pills, or non-opioids such as benzodiazepines for the purposes of managing withdrawal symptoms before resupply, both of which are likely to be counterfeit and contain unpredictable amounts of fentanyl. As with other harm reduction services, the knowledge gained from drug checking could be leveraged to promote safer use behaviors, which can move people from steps (10) to steps (1–4) rather than (11), providing protection not only in cases of uncertain potency, but when PWUD utilize other substances to try to mitigate the effects of withdrawal.

Overdose prevention centers

Places where people consume drugs under supervision and are revived if they overdose, offer the potential to eliminate the risk of fatal overdose after a person with a reduced, uncertain tolerance uses drugs of uncertain potency. As with other harm reduction services, the user is fully exposed to the risks of supply interruption as a result of seizure (10) but mitigates them by preventing what would otherwise be a fatal overdose (11) either through an effective reversal, or preventive measures, moving the person to point (4) in the model. Similar efforts may also reduce risk through remote observation, such as via phone, app, biometric sensors, or motion detectors (Lombardi et al., 2023).

Decriminalization of drug possession

Attempted in Oregon 2021 and subsequently reversed in 2024, decriminalization could partially mitigate the hazards of a supply interruption (6) for people dependent on opioids. It would do so by preventing or limiting the duration of the supply interruptions that occur when PWUD are arrested for possession and detained or possibly incarcerated, which are associated with increased risk of overdose (Victor et al., 2022; Zhang et al., 2022). It would not, however, prevent the interruptions that come from the apprehension of drug sellers and the seizure of their inventory, since the law did not decriminalize the distribution of drugs. In this way, successful decriminalization programs that still enforce laws against drug dealing like the one implemented in Portugal would not eliminate the risks of our model. Rather, they would lessen incidence of personal drug seizures, and the duration of supply

interruptions from incarceration, thereby lessening symptoms of withdrawal and reductions in tolerance (7). The Portuguese system of decriminalization also offers immediate, no-cost linkage to medications that treat opioid dependence (5), lowering the risks of a supply interruption through that pathway as well (Laqueur, 2015; Rego et al., 2021). The very low rate of overdose in Portugal, where heroin rather than fentanyl remains the principal source of illicit opioids, may support the hypothesis that the severity of the overdose risk described by our model is greatly increased by fentanyl's potency, and small margin of error in dosing.

Safer supply

The consistent and uninterrupted provision of opioids of known potency to people with opioid dependence, such as analgesics or pharmaceutically manufactured heroin (Ivsins et al., 2020), could limit overdose by keeping people in comparative stasis (1–4) rather than subjecting them to supply interruptions (6). While some Canadian jurisdictions have embarked on such an initiative (Young et al., 2022), the programs have high barriers for enrollment, serve small numbers of clients, and have faced implementation hurdles (Karamouzian et al., 2023), limiting their ability to reduce the overdose risk resulting from drug seizures in the larger population. The rationale for safer supply also suggests that our model may see fewer overdoses if the illicit opioids were the pharmaceutically produced analgesics that were the origin of the present opioid epidemic, although erratically dosed counterfeit pills, which have proliferated throughout the illicit opioid market (Friedman & Ciccarone, 2025; Green et al., 2022), would likely confound such a reduction.

Legalization and regulation

As with safer supply, legalization and regulation would bring the manufacture of recreationally used opioids under a regime that would closely monitor their consistency and potency and provide a means for commercial distribution that would preclude dealer-related supply interruptions. This would do two things: prevent the supply interruptions arising from police drug seizures in the first place (6) and ensure that the drugs consumed by people were regulated to the extent that their potency was consistent and well-known, regardless of whether a user experiences some type of interrupted supply or not (3 or 9).

Legalization, especially when accompanied by safer supply practices, would also likely lessen the circumstances in which people experienced withdrawal and reductions in tolerance due to extended supply interruptions (7), providing several means to escape the causal pathway from a supply interruption to fatal overdose (Emerson & Haden, 2021). It would also likely decrease the frequency of several other behaviors that contribute to overdose risk, such as rushed use, clandestine use, and variance across suppliers and between batches. Regardless of the theoretical effectiveness of this measure, it is critical to note that all of this is said without regard to the political reality that legalization is currently the least likely of the drug policy interventions discussed here to be implemented, due to a pronounced lack of political and cultural acceptance of the idea.

Discussion

The extent to which police drug seizures impact the broader community in terms of the availability and consistency of the drug supply is ultimately unknown, likely to be highly dependent on local contexts, and deserves further study. We do know, however, that police opioid seizures certainly affect the person the drugs are taken from, and their direct connections, and our model explains the elevated overdose risk that results. The strength of the POSTeR Model lies in its reliance on well-known features of opioid dependence and withdrawal, and a well-established understanding of certain basic mechanics of the illicit drug market. That people who consistently consume opioids will experience increasingly acute dependence and greater tolerance is not open to debate, and neither is the intense desire—or physiological need—for people dependent on opioids to avoid or mitigate withdrawal, which is a known motivator of risky behavior (Frank et al., 2023). The same can be said of the decreased opioid tolerance that comes from abstinence, whether voluntary or involuntary. The inconsistency in the potency and contents of the illicit drug supply in the case of heroin and fentanyl are also well-established, which underlies the main argument for safer supply initiatives (Ivsins et al., 2020).

In showing how these factors come together, the model moves from anecdotal accounts and quantitative research to a logic model that illustrates the causal chain between a drug seizure, the ensuing supply interruption, and increased exposure to overdose, underwriting our prior spatiotemporal analysis of the association between the two. If the four premises presented at the outset of this paper are correct, then they are sufficient to establish the validity of the model. It is important to recall that this validity does not depend on an actual increase in fatal overdose, but an increase in its risk, which can then be reduced by taking the appropriate precautions. We posit that many fatal overdoses occur because the desire to avoid withdrawal in the aftermath of a supply interruption is very strong, and often the reason people do not take the recommended precautions. The behavioral factors presented after the formal model further exacerbate this risk, but it does not depend on them for its validity.

Despite such strengths, our model has limitations that call for both caution and further research. Although it is an ancillary aspect of our model, we do not know how much of an elevated overdose risk can be attributed a general variance in the composition of the opioid supply, versus a variance in the composition of the fentanyl supply in particular, where small changes can yield comparably large increases in potency. The makeshift production processes employed by the illicit market, which can take place in private residences and other crude, repurposed spaces, is far removed from a proper pharmaceutical manufacturing operation, resulting in variance in the volume of the active opioid per dose. We hypothesize that compared to pharmaceutically produced and heroin-based opioids, powerful illicitly packaged synthetics such as fentanyl are inherently more difficult to safely dose, since even the smallest variations in the volume of the active opioid could yield great differences in potency.

It is also worth noting that the POSTeR Model only considers the near-term spatiotemporal effects of police drug seizures. The research findings that motivated this model considered

overdose up to three weeks after a police drug seizure (Ray et al., 2023), and POSTeR Model is meant to provide a causal explanation for events on this time horizon. It does not examine the long-term effects of drug seizures on a community, especially large ones that might have a more significant impact on the drug market. So, while we are unaware of any police drug seizure that was significant enough to have a durable effect on the price and/or availability of illicit drugs in the US, our model is not meant to describe mid- to long-term effects. It therefore cannot rule out the possibility that drug seizures of a size and type sufficient to cause a sustained supply shortage may foreclose the induction of new drug users, or promote treatment seeking among existing users, therefore lowering the community's overall rate of opioid dependence, or the extent to which this may offset the negative effects we describe here at the population level. Given the constant occurrence of police drug seizures across the nation, and the persistence and worsening of the overdose crisis, we would hypothesize this population level effect is minimal in comparison to the elevated risk of overdose.

Relatedly, as a model that draws on data from urban centers, it is unclear how the overdose risks it produces could be exacerbated or reduced by seizures in rural areas which may pose unique concerns (Dunn et al., 2016). The considerably greater distances and smaller populations involved in rural illicit drug distribution may matter (Fadanelli et al., 2020), as may economic precarity, which can limit options for replacement supplies (Pear et al., 2019). They could relate to longer timeframes for resupply that increase withdrawal symptoms with reduced access to harm reduction resources, or it may increase the likelihood that a replacement substance comes from a different supply chain with an inherently different or more volatile potency. Conversely, the tight-knit nature of small rural populations may yield more transparency and trust across dealer networks. More research is necessary to understand how geography affects the model.

Another limitation to the POSTeR Model is that it describes the effects of a supply interruption at the individual level, which can be caused by either a direct encounter with a police officer that results in an arrest of the PWUD, or the police takedown of a distributor who supplies a significant number of people in the community. In either case, the logic of the model is identical, and indicates an increase in overdose risk, but it does not distinguish between the intensity, duration, and breadth of the risk in different cases. It also does not distinguish how the risk is experienced by individuals in different ways, such as sex workers, unhoused people, or those with the financial resources or networks of trusted dealers that may better insulate them from supply interruptions. While these differences should be researched to further refine the model, one of its strengths may be its versatility across cases and populations. That said, the POSTeR Model does not account for the complexities of polysubstance use, i.e., the co-use of depressants and stimulants, or of different drug types within each class. Polysubstance use, which is increasingly common among people who use opioids (Cicero et al., 2020; Lim et al., 2021), can exacerbate overdose risks (Pergolizzi Jr et al., 2021), and our model does not account for these interaction effects.

Critically, this analysis does not adjudicate the competing priorities that drive narcotics enforcement and police drug seizures in many communities. There may be reasons for enforcement and the accompanying seizures that communities and their elected officials

find compelling despite their iatrogenic effects. For example, police seizures might provide a way to reduce serious violence among drug suppliers, or a drug selling operation may have a significant negative impact on the public order of a neighborhood, and there is a strong desire among community members for the police to reduce or eliminate it. The role of policies and laws in addressing these issues—or failing to do so—is complex and far beyond the scope of this paper. What our model does do, however, is suggest that there may be serious negative health outcomes associated with law enforcement to address these concerns, even though the approach may have community support, and be culturally ingrained in our approach to problematic substance use. If that is the case, it is incumbent upon communities to account for these outcomes. It is counter-intuitive that drug seizures can increase overdose risk, making the public's recalcitrance understandable, so the causal model discussed here may offer a critical means to foster a public understanding that could shape future support for evidence-based drug policy proposals.

The fact that policing routinely creates conditions sufficient for fatal overdose, and that they occur with considerable frequency, suggests the proposed model is a critical component of understanding how policing exacerbates the health risks faced by people with opioid dependence. In doing so, it demonstrates a significant tension between the police role of protection and rescue, in which they are expected to prioritize the sanctity of human life in a manner broadly consistent with public health (del Pozo, 2022; Goulka et al., 2021), and the potentially fatal risks generated by their principal strategy for addressing problematic substance use.

Conclusion

The POSTeR Model contributes to the body of knowledge about how criminal justice interventions intended to address the effects of addiction and overdose can have iatrogenic consequences that worsen health outcomes of people dependent on opioids. It is a problem that manifests across the criminal justice system. In the case of imprisonment, for example, the moral consequences of punishment are meant to be complemented by a period of detoxification and abstinence intended to promote recovery. Despite the underleveraged potential for evidence-based treatment to lessen these risks (Berk et al., 2022), this type of forced abstinence is neither effective nor safe for the people it is imposed on: release from jail or prison is believed to be one of the highest periods of overdose risk for people dependent on opioids (Binswanger et al., 2013; Binswanger et al., 2007). By the account here, the drug seizures by police that precede incarceration, whether they are from an individual who possesses drugs for personal use or someone with large quantities intended for distribution, comprise another mechanism that can increase fatal overdose despite being intended to reduce it. It is critical that future research continues to explore this outcome, assesses its prevalence across settings, estimates the magnitude of the effect, discerns which variables are protect against risk, and brings greater clarity to the risks imposed at the individual and community levels. While it is possible that police view the reduction in supply that results from drug seizures as *prima facie* evidence of a successful outcome, this model and the accompanying research suggest this is not the case if a reduced supply is meant to deliver the proximate public health goal of mortality reduction.

If research continues to exhibit a positive relationship between seizures and overdose, legalization and regulation of opioids would broadly incentivize the drug market to reduce or eliminate products of uncertain potency, decisively lowering the overdose risks resulting from uncertain dosing, as well as moderate the risky behaviors that result from the fear of drug seizures. Legalization, however, has yet to be even a remotely feasible political possibility in the United States, as nascent efforts at more modest forms of decriminalization were met with resistance, implemented poorly, and eventually repealed (del Pozo, 2024; Kim, 2024; Smiley-McDonald et al., 2023). It is likely that police drug seizures will remain a core feature of our response to illicit substances, and that such enforcement efforts will intensify, as the criminal enforcement of drug possession holds perpetual appeal in communities that hope it will reduce risk. To safeguard health, it is critical that we understand the full range of consequences for these and other policies based on police drug seizures.

Funding and support:

This work was supported by the National Institute on Drug Abuse (grant K01DA056654 to Dr. del Pozo), the National Institute of General Medical Sciences (grant P20GM125507 to Dr. Green), and the Centers for Disease Control and Prevention (grant R01CE003362 to Dr. Ray). The Institutes and Centers had no role in the conduct of this research or the preparation of this manuscript, which may not reflect their policies or positions.

Brandon del Pozo reports financial support was provided by National Institute on Drug Abuse. Traci Green reports financial support was provided by NIH National Institute of General Medical Sciences. Bradley Ray reports was provided by Centers for Disease Control and Prevention. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

- Ahmadi J, Jahromi MS, Ghahremani D, & London ED (2018). Single high-dose buprenorphine for opioid craving during withdrawal. *Trials*, 19(1), 675. 10.1186/s13063-018-3055-z [PubMed: 30526648]
- Ahmadi J, Sarani EM, & Jahromi MS (2020). Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study. *Ci Ji Yi Xue Za Zhi*, 32(1), 58–64. 10.4103/tcmj.tcmj_220_18
- Aleixo G, Patel T, Ani J, Ferrell WJ, Dotan E, Takvorian SU, Williams GR, Parikh RB, & Sedhom R. (2024). “Start low, go slow,” a strategy to tailor treatment dosing in older or vulnerable adults with advanced solid cancer: A systematic review and meta-analysis. *Journal of Geriatric Oncology*, 102153. 10.1016/j.jgo.2024.102153 [PubMed: 39537457]
- Atkins DN, del Pozo B, Clark MH, Andraka-Christou B, O'Donnell D, & Ray B. (2024). Disparities in the accuracy of reporting opioid overdoses to 9–1-1 by race and sex of overdose victim, Marion County, Indiana, 2011–2020. *Health & justice*, 12(1), 25. 10.1186/s40352-024-00279-4 [PubMed: 38819492]
- Baker P, Beletsky L, Avalos L, Venegas C, Rivera C, Strathdee SA, & Cepeda J. (2020). Policing Practices and Risk of HIV Infection Among People Who Inject Drugs. *Epidemiologic Reviews*, 42(1), 27–40. 10.1093/epirev/mxaa010 [PubMed: 33184637]
- Bardwell G, Small W, Lavalley J, McNeil R, & Kerr T. (2021). “People need them or else they’re going to take fentanyl and die”: A qualitative study examining the ‘problem’ of prescription opioid diversion during an overdose epidemic. *Social Science & Medicine*, 279, 113986. 10.1016/j.socscimed.2021.113986 [PubMed: 33971445]
- Barndollar H. (2023, June 26). How Manchester worked to prevent overdoses after large-scale drug trafficking bust: Risk of overdose may rise for dependent users. The

New Hampshire Bulletin. <https://newhampshirebulletin.com/2023/06/26/how-manchester-worked-to-prevent-overdoses-after-large-scale-drug-trafficking-bust/>

- Bennett AS, Freeman R, Des Jarlais DC, & Aronson ID (2020). Reasons people who use opioids do not accept or carry no-cost naloxone: qualitative interview study. *JMIR formative research*, 4(12), e22411. [PubMed: 33355094]
- Berk J, del Pozo B, Rich JD, & Lee JD (2022). Injecting Opioid Use Disorder Treatment in Jails and Prisons: The Potential of Extended-release Buprenorphine in the Carceral Setting. *Journal of Addiction Medicine*. https://journals.lww.com/journaladdictionmedicine/Fulltext/9000/Injecting_Opioid_Use_Disorder_Treatment_in_Jails.98962.aspx
- Binswanger IA, Blatchford PJ, Lindsay RG, & Stern MF (2011). Risk factors for all-cause, overdose and early deaths after release from prison in Washington state. *Drug and Alcohol Dependence*, 117(1), 1–6. 10.1016/j.drugalcdep.2010.11.029 [PubMed: 21295414]
- Binswanger IA, Blatchford PJ, Mueller SR, & Stern MF (2013). Mortality After Prison Release: Opioid Overdose and Other Causes of Death, Risk Factors, and Time Trends From 1999 to 2009. *Annals of internal medicine*, 159(9), 592–600. 10.7326/0003-4819-159-9-201311050-00005 [PubMed: 24189594]
- Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, & Koepsell TD (2007). Release from Prison — A High Risk of Death for Former Inmates. *The New England Journal of Medicine*, 356(2), 157–165. 10.1056/NEJMsa064115 [PubMed: 17215533]
- Bluthenthal RN, Simpson K, Ceasar RC, Zhao J, Wenger L, & Kral AH (2020). Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. *Drug and Alcohol Dependence*, 211, 107932. 10.1016/j.drugalcdep.2020.107932 [PubMed: 32199668]
- Boyer EW, Babu KM, Adkins JE, McCurdy CR, & Halpern JH (2008). Self-treatment of opioid withdrawal using kratom (*Mitragynia speciosa korth*). *Addiction*, 103(6), 1048–1050. [PubMed: 18482427]
- Brinkley-Rubinstein L, Macmadu A, Marshall BDL, Heise A, Ranapurwala SI, Rich JD, & Green TC (2018). Risk of fentanyl-involved overdose among those with past year incarceration: Findings from a recent outbreak in 2014 and 2015. *Drug and Alcohol Dependence*, 185, 189–191. 10.1016/j.drugalcdep.2017.12.014 [PubMed: 29459328]
- Byanyima JJ, Li X, Vesslee SA, Kranzler HR, Shi Z, & Wiers CE (2023). Metabolic Profiles Associated with Opioid Use and Opioid Use Disorder: a Narrative Review of the Literature. *Current Addiction Reports*, 10(3), 581–593. 10.1007/s40429-023-00493-4 [PubMed: 37982033]
- Byles H, Sedaghat N, Rider N, Rioux W, Loverock A, Seo B, Dhanoa A, Orr T, Dunnewold N, & Tjosvold L. (2024). Barriers to calling emergency services amongst people who use substances in the event of overdose: a scoping review. *International Journal of Drug Policy*, 132, 104559. [PubMed: 39197374]
- Cano M, Timmons P, Hooten M, Sweeney K, & Oh S. (2024). A scoping review of law enforcement drug seizures and overdose mortality in the United States. *International Journal of Drug Policy*, 124, 104321. 10.1016/j.drugpo.2024.104321 [PubMed: 38211403]
- Carroll JJ, Rich JD, & Green TC (2020). The protective effect of trusted dealers against opioid overdose in the U.S. *International Journal of Drug Policy*, 78, 102695. 10.1016/j.drugpo.2020.102695 [PubMed: 32143185]
- Cherryholmes CH (1992). Notes on pragmatism and scientific realism. *Educational researcher*, 21(6), 13–17.
- Childress AR, McLellan AT, Ehrman R, & O'Brien CP (1988). Classically conditioned responses in opioid and cocaine dependence: a role in relapse. *NIDA Res Monogr*, 84, 25–43. [PubMed: 3147384]
- Cicero TJ, Ellis MS, & Kasper ZA (2020). Polysubstance Use: A Broader Understanding of Substance Use During the Opioid Crisis. *American Journal of Public Health*, 110(2), 244–250. 10.2105/ajph.2019.305412 [PubMed: 31855487]
- Collins AB, Kaplowitz E, Bastani P, McKee H, Whitaker D, Hallowell BD, & McKenzie M. (2024). “I Don’t Go Overboard”: Perceptions of Overdose Risk and Risk Reduction Strategies

- among People Who Use Drugs in Rhode Island. *Substance Use & Misuse*, 59(5), 673–679. 10.1080/10826084.2023.2294968 [PubMed: 38124349]
- Cooper H, Moore L, Gruskin S, & Krieger N. (2005). The impact of a police drug crackdown on drug injectors' ability to practice harm reduction: A qualitative study. *Social Science & Medicine*, 61(3), 673–684. 10.1016/j.socscimed.2004.12.030 [PubMed: 15899325]
- Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, & McLaren J. (2011). Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. *Addiction*, 106(1), 32–51. 10.1111/j.1360-0443.2010.03140.x [PubMed: 21054613]
- Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, & Larney S. (2019). Global patterns of opioid use and dependence: harms to populations, interventions, and future action. *The Lancet*, 394(10208), 1560–1579. 10.1016/S0140-6736(19)32229-9
- del Pozo B. (2022). *The Police and The State: Security, Social Cooperation, and the Public Good*. Cambridge University Press.
- del Pozo B. (2024, April 25). Why the drug reform movement looks like it's failing. *The Boston Globe*. <https://www.bostonglobe.com/2024/04/25/opinion/oregon-drug-decriminalization-what-reformers-missed/>
- Dennis F. (2016). Encountering “triggers” drug–body–world entanglements of injecting drug use. *Contemporary Drug Problems*, 43(2), 126–141.
- Doe-Simkins M, & Wheeler EJ (2025). Overdose Education and Naloxone Distribution: An Evidence-Based Practice That Warrants Course Correcting. In (Vol. 115, pp. 6–8): American Public Health Association.
- Dumas EO, & Pollack GM (2008). Opioid Tolerance Development: A Pharmacokinetic/ Pharmacodynamic Perspective. *The AAPS Journal*, 10(4), 537–551. 10.1208/s12248-008-9056-1 [PubMed: 18989788]
- Dunn KE, Barrett FS, Yezep-Laubach C, Meyer AC, Hruska BJ, Petrush K, Berman S, Sigmon SC, Fingerhood M, & Bigelow GE (2016). Opioid overdose experience, risk behaviors, and knowledge in drug users from a rural versus an urban setting. *Journal of Substance Abuse Treatment*, 71, 1–7. [PubMed: 27672239]
- Dunn KE, Bergeria CL, Ware OD, & Strain EC (2023). The opioid withdrawal syndrome: presentation, measurement, and management. *The Oxford Handbook of Opioids and Opioid Use Disorder*, 194.
- El-Sabawi T. (2024). Death by Withdrawal. *UCLA L. Rev*, 71, 378.
- Emerson B, & Haden M. (2021). A public health based vision for the management and regulation of opioids. *International Journal of Drug Policy*, 91, 103201. [PubMed: 33785246]
- Fadanelli M, Cloud DH, Ibragimov U, Ballard AM, Prood N, Young AM, & Cooper HLF (2020). People, places, and stigma: A qualitative study exploring the overdose risk environment in rural Kentucky. *International Journal of Drug Policy*, 85, 102588. 10.1016/j.drugpo.2019.11.001 [PubMed: 31753603]
- Frank D, Elliott L, Cleland CM, Walters SM, Joudrey PJ, Russell DM, Meyerson BE, & Bennett AS (2023). “As safe as possible”: a qualitative study of opioid withdrawal and risk behavior among people who use illegal opioids. *Harm Reduction Journal*, 20(1), 158. [PubMed: 37891630]
- Freye E, & Latasch L. (2003). [Development of opioid tolerance -- molecular mechanisms and clinical consequences]. *Anesthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS*, 38(1), 14–26. 10.1055/s-2003-36558 [PubMed: 12522725]
- Friedman J, & Ciccarone D. (2025). The public health risks of counterfeit pills. *The Lancet Public Health*, 10(1), e58–e62. [PubMed: 39755415]
- Gökçınar A, Çakanyıldırım M, Price T, & Adams MC (2022). Balanced opioid prescribing via a clinical trade-off: Pain relief vs. adverse effects of discomfort, dependence, and tolerance/hypersensitivity. *Decision Analysis*, 19(4), 297–318.
- Goulka J, del Pozo B, & Beletsky L. (2021). From public safety to public health: Re-envisioning the goals and methods of policing. *Journal of Community Safety and Well-Being*, 6(1). 10.35502/jcswb.184

- Green TC, Olson R, Jarczyk C, Erowid E, Erowid F, Thyssen S, & Wightman R. (2022). Implementation and Uptake of the Massachusetts Drug Supply Data Stream: A Statewide Public Health-Public Safety Partnership Drug Checking Program. *Journal of Public Health Management and Practice*, 28(S 6), S347–S354. 10.1097/PHH.0000000000001581 [PubMed: 36194805]
- Greenland S, & Brumback B. (2002). An overview of relations among causal modelling methods. *International Journal of Epidemiology*, 31(5), 1030–1037. 10.1093/ije/31.5.1030 [PubMed: 12435780]
- Hall OT, Vilensky M, Teater JE, Bryan C, Rood K, Niedermier J, Entrup P, Gorka S, King A, & Williams DA (2024). Withdrawal catastrophizing scale: initial psychometric properties and implications for the study of opioid use disorder and hyperkatifeia. *The American journal of drug and alcohol abuse*, 1–13.
- Hanoa K, Bilgrei OR, & Buvik K. (2024). Injecting Alone. The Importance of Perceived Safety, Stigma and Pleasure for Solitary Injecting. *Journal of Drug Issues*, 54(1), 74–89. 10.1177/00220426231151377
- Hedden-Clayton B, Cochran J, Carroll JJ, Kral AH, Victor G, Comartin E, & Ray B. (2024). “If everyone knew about this, how many lives could we save?”: Do drug suppliers have a role in reducing overdose risk? *Drug and Alcohol Dependence Reports*, 12, 100250. 10.1016/j.dadr.2024.100250 [PubMed: 39055120]
- Hochstatter KR, Nordeck C, Mitchell SG, Schwartz RP, Welsh C, & Gryczynski J. (2023). Polysubstance use and post-discharge mortality risk among hospitalized patients with opioid use disorder. *Preventive medicine reports*, 36, 102494. [PubMed: 38116282]
- Holland A, Brothers TD, Lewer D, Maynard OM, & Southwell M. (2024). “Safer supply” alternatives to toxic unregulated drug markets. In (Vol. 384): *British Medical Journal Publishing Group*.
- Hser Y-I, Hoffman V, Grella CE, & Anglin MD (2001). A 33-Year Follow-up of Narcotics Addicts. *Archives of General Psychiatry*, 58(5), 503–508. 10.1001/archpsyc.58.5.503 [PubMed: 11343531]
- Hser YI, Evans E, Grella C, Ling W, & Anglin D. (2015). Long-term course of opioid addiction. *Harv Rev Psychiatry*, 23(2), 76–89. 10.1097/hrp.0000000000000052 [PubMed: 25747921]
- Ivsins A, Boyd J, Beletsky L, & McNeil R. (2020). Tackling the overdose crisis: the role of safe supply. *International Journal of Drug Policy*, 102769. 10.1016/j.drugpo.2020.102769 [PubMed: 32446183]
- Jagosh J. (2020). Retroductive theorizing in Pawson and Tilley’s applied scientific realism. *Journal of Critical Realism*, 19(2), 121–130. 10.1080/14767430.2020.1723301
- Jeffery MM, Chaisson CE, Hane C, Rumanes L, Tucker J, Hang L, McCoy R, Chen CL, Bicket MC, Hooten WM, Larochelle M, Becker WC, Kornegay C, Racoosin JA, & Sanghavi D. (2020). Assessment of Potentially Inappropriate Prescribing of Opioid Analgesics Requiring Prior Opioid Tolerance. *JAMA network open*, 3(4), e202875–e202875. 10.1001/jamanetworkopen.2020.2875 [PubMed: 32293684]
- Jones CM, Noonan RK, & Compton WM (2020). Prevalence and correlates of ever having a substance use problem and substance use recovery status among adults in the United States, 2018. *Drug and Alcohol Dependence*, 214, 108169. [PubMed: 32682218]
- Joudrey PJ, Khan MR, Wang EA, Scheidell JD, Edelman EJ, McInnes DK, & Fox AD (2019). A conceptual model for understanding post-release opioid-related overdose risk. *Addict Sci Clin Pract*, 14(1), 17. 10.1186/s13722-019-0145-5 [PubMed: 30982468]
- Karamouzian M, Rafat B, Kolla G, Urbanoski K, Atkinson K, Bardwell G, Bonn M, Touesnard N, Henderson N, Bowles J, Boyd J, Brunelle C, Eeuwes J, Fikowski J, Gomes T, Guta A, Hyshka E, Ivsins A, Kennedy MC, . . . Werb D. (2023). Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: A qualitative analysis. *International Journal of Drug Policy*, 120, 104157. 10.1016/j.drugpo.2023.104157 [PubMed: 37574645]
- Kelly JF, Bergman BG, Hoepfner BB, Vilsaint C, & White WL (2017). Prevalence and pathways of recovery from drug and alcohol problems in the United States population: Implications for practice, research, and policy. *Drug and Alcohol Dependence*, 181, 162–169. [PubMed: 29055821]
- Kesten JM, Holder E, Ayres R, Ellis P, Taylor S, Hickman M, & Henderson G. (2022). Changes in the development of opioid tolerance on re-exposure among people who use heroin: A qualitative study. *PLoS One*, 17(6), e0269379. 10.1371/journal.pone.0269379 [PubMed: 35737700]

- Kim T. (2024, January 15). A drug decriminalization fight erupts in Oregon. *The New Yorker*. <https://www.newyorker.com/magazine/2024/01/22/a-new-drug-war-in-oregon>
- Kumar V. (2016, January 20). Former opioid users are at a greater risk of overdosing than the newly addicted. *JAX Blog*. <https://www.jax.org/news-and-insights/jax-blog/2016/june/former-opioid-users-at-greater-risk-of-overdose-than-newly-addicted#>
- Laqueu H. (2015). Uses and Abuses of Drug Decriminalization in Portugal. *Law & Social Inquiry*, 40(3), 746–781. <http://www.jstor.org/stable/24545832>
- Larnder A, Saatchi A, Borden SA, Moa B, Gill CG, Wallace B, & Hore D. (2022). Variability in the unregulated opioid market in the context of extreme rates of overdose. *Drug and Alcohol Dependence*, 235, 109427. [10.1016/j.drugalcdep.2022.109427](https://doi.org/10.1016/j.drugalcdep.2022.109427) [PubMed: 35405459]
- Leplin J. (1984). *Scientific realism* (Vol. 323). Univ of California Press.
- Lim JK, Earlywine JJ, Bagley SM, Marshall BDL, & Hadland SE (2021). Polysubstance Involvement in Opioid Overdose Deaths in Adolescents and Young Adults, 1999–2018. *JAMA Pediatrics*, 175(2), 194–196. [10.1001/jamapediatrics.2020.5035](https://doi.org/10.1001/jamapediatrics.2020.5035) [PubMed: 33226412]
- Lombardi AR, Arya R, Rosen JG, Thompson E, Welwean R, Tardif J, Rich JD, & Park JN (2023). Overdose detection technologies to reduce solitary overdose deaths: a literature review. *International journal of environmental research and public health*, 20(2), 1230. [PubMed: 36673987]
- Lötsch J, Skarke C, Liefhold J, & Geisslinger G. (2004). Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. *Clinical pharmacokinetics*, 43, 983–1013. [PubMed: 15530129]
- Mann B (2023, November 19). Drug users aren't all ready to quit. *NPR Weekend Edition*. <https://www.npr.org/2023/11/19/1212536008/fentanyl-xylazine-drugs-addiction-stigma-louise-vincent>
- Mark TL, & Parish W. (2019). Opioid medication discontinuation and risk of adverse opioid-related health care events. *Journal of Substance Abuse Treatment*, 103, 58–63. [10.1016/j.jsat.2019.05.001](https://doi.org/10.1016/j.jsat.2019.05.001) [PubMed: 31079950]
- Massaly N, Morón JA, & Al-Hasani R. (2016). A trigger for opioid misuse: chronic pain and stress dysregulate the mesolimbic pathway and kappa opioid system. *Frontiers in neuroscience*, 10, 480. [PubMed: 27872581]
- Mateu-Gelabert P, Sandoval M, Meylaks P, Wendel T, & Friedman SR (2010). Strategies to avoid opiate withdrawal: Implications for HCV and HIV risks. *International Journal of Drug Policy*, 21(3), 179–185. [10.1016/j.drugpo.2009.08.007](https://doi.org/10.1016/j.drugpo.2009.08.007) [PubMed: 19786343]
- McFadden G. (2023, June 8). Manchester officials deploy overdose response team following drug bust. *New Hampshire Public Radio*. Retrieved April 28 from <https://www.nhpr.org/nh-news/2023-06-08/manchester-deploys-overdose-response-team-following-drug-bust>
- Meacham MC, Nobles AL, Tompkins DA, & Thrul J. (2022). “I got a bunch of weed to help me through the withdrawals”: Naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums. *PLoS One*, 17(2), e0263583. [PubMed: 35134074]
- META PHI. (2024). Acknowledgment of Loss of Opioid Tolerance Following Withdrawal. Ontario Ministry of Health. Retrieved January 20 from https://www.metaphi.ca/wp-content/uploads/WMS_4.3_AcknowledgmentToleranceLoss.pdf
- Mocenni C, Montefrancesco G, & Tiezzi S. (2019). A model of spontaneous remission from addiction. *International Journal of Applied Behavioral Economics (IJABE)*, 8(1), 21–48.
- Monroe SC, & Radke AK (2023). Opioid withdrawal: role in addiction and neural mechanisms. *Psychopharmacology*, 240(7), 1417–1433. [PubMed: 37162529]
- Na PJ, Deak JD, Kranzler HR, Pietrzak RH, & Gelernter J. (2024). Genetic and non-genetic predictors of risk for opioid dependence. *Psychological Medicine*, 54(8), 1779–1786. [PubMed: 38317430]
- National Academies of Sciences Engineering & Medicine. (2019). *Medications for Opioid Use Disorder Save Lives*. National Academies Press. [10.17226/25310](https://doi.org/10.17226/25310)
- Norcross JC, Krebs PM, & Prochaska JO (2011). Stages of change. *Journal of clinical psychology*, 67(2), 143–154. [PubMed: 21157930]
- O'Donnell J, Tanz LJ, Miller KD, Dinwiddie AT, Wolff J, Mital S, Obiekwe R, & Mattson CL (2023). Drug overdose deaths with evidence of counterfeit pill use—United States, July 2019–December 2021. *MMWR. Morbidity and Mortality Weekly Report*, 72.

- Patton D, & Best D. (2024). Motivations for change in drug addiction recovery: Turning points as the antidotes to the pains of recovery. *Journal of Drug Issues*, 54(3), 346–366.
- Pawson R, & Tilley N. (1997). An introduction to scientific realist evaluation. In *Evaluation for the 21st century: A handbook*. (pp. 405–418). Sage Publications, Inc. 10.4135/9781483348896.n29
- Pear VA, Ponicki WR, Gaidus A, Keyes KM, Martins SS, Fink DS, Rivera-Aguirre A, Gruenewald PJ, & Cerdá M. (2019). Urban-rural variation in the socioeconomic determinants of opioid overdose. *Drug and Alcohol Dependence*, 195, 66–73. [PubMed: 30592998]
- Peppin JF, Raffa RB, & Schatman ME (2020). The polysubstance overdose-death crisis. In (pp. 3405–3408): Taylor & Francis.
- Pergolizzi JV Jr, Dahan A, LeQuang JA, & Raffa RB (2021). The conundrum of polysubstance overdose. *Journal of Clinical Pharmacy and Therapeutics*, 46(5), 1189–1193. 10.1111/jcpt.13362 [PubMed: 33460173]
- Pergolizzi JV Jr, Raffa RB, & Rosenblatt MH (2020). Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. *Journal of Clinical Pharmacy and Therapeutics*, 45(5), 892–903. [PubMed: 31986228]
- Pourtaher E, Payne ER, Fera N, Rowe K, Leung S-YJ, Stancliff S, Hammer M, Vinehout J, & Dailey MW (2022). Naloxone administration by law enforcement officers in New York State (2015–2020). *Harm Reduction Journal*, 19(1), 102. 10.1186/s12954-022-00682-w [PubMed: 36123614]
- Preiss A, Baumgartner P, Edlund MJ, & Bobashev GV (2022). Using named entity recognition to identify substances used in the self-medication of opioid withdrawal: natural language processing study of Reddit data. *JMIR formative research*, 6(3), e33919. [PubMed: 35353047]
- Prochaska JO, & Norcross JC (2001). Stages of change. *Psychotherapy: theory, research, practice, training*, 38(4), 443.
- Psillos S. (2005). *Scientific realism: How science tracks truth*. Routledge.
- Ray B, Korzeniewski SJ, Mohler G, Carroll JJ, del Pozo B, Victor G, Huynh P, & Hedden BJ (2023). Spatiotemporal Analysis Exploring the Effect of Law Enforcement Drug Market Disruptions on Overdose, Indianapolis, Indiana, 2020–2021. *American Journal of Public Health*, 113(7), 750–758. 10.2105/ajph.2023.307291 [PubMed: 37285563]
- Rego X, Oliveira MJ, Lameira C, & Cruz OS (2021). 20 years of Portuguese drug policy - developments, challenges and the quest for human rights. *Substance abuse treatment, prevention and policy*, 16(1), 1–59. 10.1186/s13011-021-00394-7 [PubMed: 33388062]
- Rhodes B, Costenbader B, Wilson L, Hershow R, Carroll J, Zule W, Golin C, & Brinkley-Rubinstein L. (2019). Urban, individuals of color are impacted by fentanyl-contaminated heroin. *Int J Drug Policy*, 73, 1–6. 10.1016/j.drugpo.2019.07.008 [PubMed: 31330274]
- Rosen JG, Glick JL, Zhang L, Cooper L, Olatunde PF, Pelaez D, Rouhani S, Sue KL, & Park JN (2023). Safety in solitude? Competing risks and drivers of solitary drug use among women who inject drugs and implications for overdose detection. *Addiction*, 118(5), 847–854. 10.1111/add.16103 [PubMed: 36468191]
- Rosenblum D, Unick J, & Ciccarone D. (2020). The rapidly changing US illicit drug market and the potential for an improved early warning system: evidence from Ohio drug crime labs. *Drug and Alcohol Dependence*, 208, 107779. [PubMed: 31931266]
- Sampson RJ, & Laub JH (1993). Crime in the making: Pathways and turning points through life. *Crime & Delinquency*, 39(3), 396–396.
- Shah M, & Huecker MR (2018). Opioid withdrawal.
- Smiley-McDonald HM, Attaway PR, Wenger LD, Greenwell K, Lambdin BH, & Kral AH (2023). “All carrots and no stick”: Perceived impacts, changes in practices, and attitudes among law enforcement following drug decriminalization in Oregon State, USA. *International Journal of Drug Policy*, 118, 104100. 10.1016/j.drugpo.2023.104100 [PubMed: 37356287]
- Smyth S. (2017). The Use of Narcan in Criminal Investigations by Law Enforcement and the Consequences of Police Involvement in the Opioid Epidemic. *Health Law.*, 30, 31.
- Suen LW, Davidson PJ, Browne EN, Lambdin BH, Wenger LD, & Kral AH (2022). Effect of an Unsanctioned Safe Consumption Site in the United States on Syringe Sharing, Rushed Injections, and Isolated Injection Drug Use: A Longitudinal Cohort Analysis. *JAIDS Journal of Acquired*

Immune Deficiency Syndromes, 89(2), 172–177. 10.1097/QAI.0000000000002849 [PubMed: 34723925]

- Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, & Mackey S. (2017). Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. *BMJ*, 356.
- Ti L, Hayashi K, Kaplan K, Suwannawong P, Wood E, & Kerr T. (2015). Contextual factors associated with rushed injecting among people who inject drugs in Thailand. *Prevention Science*, 16, 313–320. [PubMed: 24599484]
- Tobias S, Grant CJ, Laing R, Arredondo J, Lysyshyn M, Buxton J, Tupper KW, Wood E, & Ti L. (2021). Time-Series Analysis of Fentanyl Concentration in the Unregulated Opioid Drug Supply in a Canadian Setting. *American journal of epidemiology*, 191(2), 241–247. 10.1093/aje/kwab129
- Townsend T, Blostein F, Doan T, Madson-Olson S, Galecki P, & Hutton DW (2020). Cost-effectiveness analysis of alternative naloxone distribution strategies: First responder and lay distribution in the United States. *International Journal of Drug Policy*, 75, 102536. 10.1016/j.drugpo.2019.07.031 [PubMed: 31439388]
- van der Meulen E, Chu SKH, & Butler-McPhee J. (2021). “That’s why people don’t call 911”: Ending routine police attendance at drug overdoses. *International Journal of Drug Policy*, 88, 103039. 10.1016/j.drugpo.2020.103039 [PubMed: 33227637]
- Victor G, Zettner C, Huynh P, Ray B, & Sights E. (2022). Jail and overdose: assessing the community impact of incarceration on overdose. *Addiction*, 117(2), 433–441. 10.1111/add.15640 [PubMed: 34251065]
- Victor GA, Strickland JC, Kheibari AZ, & Flaherty C. (2020). A mixed-methods approach to understanding overdose risk-management strategies among a nationwide convenience sample. *International Journal of Drug Policy*, 86, 102973. [PubMed: 33049591]
- Ware OD, & Dunn KE (2023). Clinically meaningful individual differences in opioid withdrawal expression. *Experimental and clinical psychopharmacology*.
- Weisenthal K, Kimme SD, Kehoe J, Larochelle MR, Walley AY, & Taylo JL. (2022). Effect of police action on low-barrier substance use disorder service utilization. *Harm Reduction Journal*, 19(1), 86. 10.1186/s12954-022-00668-8 [PubMed: 35906660]
- Werb D, Wood E, Small W, Strathdee S, Li K, Montaner J, & Kerr T. (2008). Effects of police confiscation of illicit drugs and syringes among injection drug users in Vancouver. *International Journal of Drug Policy*, 19(4), 332–338. 10.1016/j.drugpo.2007.08.004 [PubMed: 17900888]
- White MD, Watts S, Orosco C, Perrone D, & Malm A. (2022). Leveraging Body-Worn Camera Footage to Better Understand Opioid Overdoses and the Impact of Police-Administered Naloxone. *American Journal of Public Health*, 112(9), 1326–1332. 10.2105/ajph.2022.306918 [PubMed: 35862885]
- Wiese B, & Wilson-Poe AR (2018). Emerging evidence for cannabis’ role in opioid use disorder. *Cannabis and cannabinoid research*, 3(1), 179–189. [PubMed: 30221197]
- Wilder-Smith OH (2005). Opioid use in the elderly. *European Journal of Pain*, 9(2), 137–140. [PubMed: 15737802]
- Williams AR, Samples H, Crystal S, & Olfson M. (2020). Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. *American Journal of Psychiatry*, 177(2), 117–124. [PubMed: 31786933]
- Young S, Kolla G, McCormack D, Campbell T, Leece P, Strike C, Srivastava A, Antoniou T, Bayoumi AM, & Gomes T. (2022). Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. *International Journal of Drug Policy*, 102, 103601. [PubMed: 35124413]
- Zhang A, Balles JA, Nyland JE, Nguyen TH, White VM, & Zgierska AE (2022). The relationship between police contacts for drug use-related crime and future arrests, incarceration, and overdoses: a retrospective observational study highlighting the need to break the vicious cycle. *Harm Reduction Journal*, 19(1), 67. 10.1186/s12954-022-00652-2 [PubMed: 35761290]

- Zoorob M. (2019). Fentanyl shock: The changing geography of overdose in the United States. *International Journal of Drug Policy*, 70, 40–46. 10.1016/j.drugpo.2019.04.010 [PubMed: 31079029]
- Zoorob MJ, Park JN, Kral AH, Lambdin BH, & del Pozo B. (2024). Drug Decriminalization, Fentanyl, and Fatal Overdoses in Oregon. *JAMA network open*, 7(9), e2431612–e2431612. 10.1001/jamanetworkopen.2024.31612 [PubMed: 39235814]

Highlights

- Studies show an association between police opioid seizures and fatal overdose.
- This model presents physical and behavioral causes of this positive relationship.
- Reducing the disruptive outcomes of police opioid seizures can reduce overdose.
- Police opioid seizures can worsen the problem of overdose they intend to address.



Author Manuscript




Figure 2. Interventions to prevent overdose in the aftermath of a police drug seizure mapped onto the Stages of Change